知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

102 条记录 (耗时 0.041 秒)

    Vasoactive hormone-based stratification of patients suffering from diseases related to endothelial function/dysfunction
    7.
    发明授权
    Vasoactive hormone-based stratification of patients suffering from diseases related to endothelial function/dysfunction 有权
    患有与内皮功能/功能障碍相关的疾病的患者的基于血管活性激素的分层

    公开(公告)号：US09229013B2

    公开(公告)日：2016-01-05

    申请号：US13318488

    申请日：2010-05-05

    申请人： Andreas Bergmann ,  Joachim Struck ,  Oliver Hartmann ,  Leong Loke Ng

    发明人： Andreas Bergmann ,  Joachim Struck ,  Oliver Hartmann ,  Leong Loke Ng

    IPC分类号： G01N31/00 ,  G01N33/53 ,  G01N33/74

    CPC分类号： G01N33/74 ,  G01N2333/5754 ,  G01N2333/5757 ,  G01N2333/58 ,  G01N2800/52

    摘要： The present invention relates to a method for the stratification of a subject having an acute or a chronic disease, wherein the disease affects endothelial function/dysfunction, comprising the steps of (i) taking a sample of bodily fluid from the subject; (ii) determining in the sample of bodily fluid the concentration of a vasoactive hormone or fragments thereof or precursors or fragments thereof having a length of at least 12 amino acid residues; (iii) stratifying the subjects into either of the categories: (a) responder to a medication for treatment of the disease, (b) non-responder to a medication for treatment of the disease not showing an unfavorable effect after having received the medication; (c) subjects showing an unfavorable effect after having received the medication. The invention also relates to the use of an antibody or a functional fragment thereof in the method according to the invention.

    摘要翻译： 本发明涉及一种用于对患有急性或慢性疾病的受试者进行分层的方法，其中所述疾病影响内皮功能/功能障碍，包括以下步骤：（i）从受试者身上取出体液样品; （ii）在体液样品中测定长度为至少12个氨基酸残基的血管活性激素或其片段或其前体或其片段的浓度; （iii）将受试者分为以下任一类别：（a）用于治疗疾病的药物的应答者，（b）不接受用于治疗在接受药物后不显示不利影响的疾病的药物; （c）在接受药物后显示不利影响的受试者。 本发明还涉及抗体或其功能片段在本发明方法中的用途。

    Method for determining amino-terminal proANP in patients having a cardiac disease or being suspected of developing or having a cardiac disease
    8.
    发明授权
    Method for determining amino-terminal proANP in patients having a cardiac disease or being suspected of developing or having a cardiac disease 有权
    在患有心脏病或疑似发展或患有心脏病的患者中测定氨基末端proANP的方法

    公开(公告)号：US08647830B2

    公开(公告)日：2014-02-11

    申请号：US12598982

    申请日：2008-05-06

    申请人： Andreas Bergmann ,  Jana Papassotiriou ,  Joachim Struck ,  Nils Morgenthaler ,  Stefan Anker

    发明人： Andreas Bergmann ,  Jana Papassotiriou ,  Joachim Struck ,  Nils Morgenthaler ,  Stefan Anker

    IPC分类号： G01N33/53 ,  G01N31/00

    CPC分类号： G01N33/74 ,  G01N2333/58 ,  G01N2800/324

    摘要： The present invention relates to an in vitro method for medical diagnosis, prognosis and therapy follow-up for patients having a cardiac disease or being suspected of developing or having a cardiac disease comprising the steps of: providing a sample of a patient having a cardiac disease or being suspected of developing or having a cardiac disease, determining amino-terminal proANp or partial peptides thereof having from 12 to 98 amino acids in said sample using at least one antibody that binds specifically to a partial sequence of amino-terminal proANP, attributing the determined amino-terminal proANP level or the level of partial peptides thereof to a clinical picture wherein the attribution is carried out independent of the BMI of the patient. The present invention further concerns a rapid test assay and a kit for conducting the method of the present invention and the use of antibodies suitable for the method and assays according to the present invention.

    摘要翻译： 本发明涉及用于患有心脏病或被怀疑发展或患有心脏病的患者的医学诊断，预后和治疗随访的体外方法，其包括以下步骤：提供患有心脏病的患者的样品 或怀疑发展或患有心脏病，使用至少一种与氨基末端proANP的部分序列特异性结合的抗体，确定所述样品中具有12至98个氨基酸的氨基末端proANp或其部分肽，归因于 确定的氨基末端proANP水平或其部分肽的水平到临床图片，其中归因独立于患者的BMI进行。 本发明还涉及用于进行本发明方法的快速测试测定和试剂盒以及适用于本发明方法和测定的抗体的应用。

    RISK ASSESSMENT FOR ANTIBOTICS TREATMENT IN PATIENTS SUFFERING FROM PRIMARY NON-INFECTIOUS DISEASE BY DETERMINING THE LEVEL OF PROCALCITONIN
    10.
    发明申请
    RISK ASSESSMENT FOR ANTIBOTICS TREATMENT IN PATIENTS SUFFERING FROM PRIMARY NON-INFECTIOUS DISEASE BY DETERMINING THE LEVEL OF PROCALCITONIN 有权
    通过确定原发性肝炎的水平，从主要的非感染性疾病患者的抗生素治疗风险评估

    公开(公告)号：US20120100635A1

    公开(公告)日：2012-04-26

    申请号：US13264252

    申请日：2010-04-14

    申请人： Andreas Bergmann ,  Joachim Struck

    发明人： Andreas Bergmann ,  Joachim Struck

    IPC分类号： G01N33/566 ,  C07K16/18

    CPC分类号： G01N33/74 ,  G01N2333/585 ,  G01N2800/32 ,  G01N2800/325

    摘要： The present invention relates to a diagnostic method for the identification of a subject suffering from a primary non-infectious disease having an increased risk of an adverse outcome potentially being induced by the administration of an antibiotic to said subject comprising the determination of the level of Procalcitonin (PCT) or a fragment thereof or a precursor or fragment thereof having a length of at least 12 amino acid residues in a sample of a bodily fluid from said subject and the correlation of the determined level to a potential risk induced by the administration of an antibiotic.

    摘要翻译： 本发明涉及用于鉴定患有主要非传染性疾病的受试者的诊断方法，所述主要非传染性疾病的潜在可能通过向所述受试者施用抗生素诱导的不利结果的风险增加，包括测定降钙素原水平 （PCT）或其片段或其在来自所述受试者的体液样品中具有至少12个氨基酸残基长度的前体或片段，以及所确定的水平与通过施用所引起的潜在风险的相关性 抗生素。